Steven Nichtberger bought CABA once, on Jan 21, 2026

Steven Nichtberger, M.D. is the President, Chief Executive Officer, Chairman, and Co-Founder of Cabaletta Bio, Inc. (NASDAQ: CABA), a clinical-stage biotechnology company developing targeted cellular therapies, particularly CAR T therapies, for B cell-mediated autoimmune diseases.( He has led the company since its founding in 2017, spun out from the University of Pennsylvania, and recently purchased 45,000 shares on January 21, 2026, at an average price of $2.2395, bringing his direct ownership to over 1 million shares.(

Dr. Nichtberger's career highlights include serving as founding CEO of Tengion from 2004 to 2011, where he earned the Ernst & Young Entrepreneur of the Year award in 2008, and earlier roles at Merck from 1995 to 2003 as head of global marketing and in commercial operations.( He is a senior fellow and adjunct professor at the Wharton School of the University of Pennsylvania, serves on the executive committee of Main Line Health's board of governors, and has held board positions with the Alliance for Regenerative Medicine, Pennsylvania Bio, and Biotechnology Industry Organization.( Dr. Nichtberger holds an M.D. from the State University of New York at Buffalo, a B.S. from the Wharton School, and a B.A. from the College of Arts & Sciences at the University of Pennsylvania, with medical training completed at Mount Sinai Medical Center.(

Written by Perplexity from public sources.